I'm so busy packing up and getting ready to move that I haven't had time to read all the "bash and trash" here, of late! Keep up the good fight fellas!! This, too, shall pass!
Liquidity is an issue right now. I was going to add 1K shares at $7.60 and very little of it filled, moved the bid up above the ask and still filled in a few shares at a time.
Same thing happened when OCAT did their reverse split ... relax, it will all get straightened out.
When a r/s happens, the trading is a bit off for a day or so because, believe it or not, it takes all of the brokerage houses a while to get all of their ducks in a row. Have been through a couple of them and that was the case there, fwiw. We'll see.
Throw in EXAS for good measure! Over-reaction on both, but we'll see. The biotech ETFs are red, AGAIN. I, personally think we're basing pretty solidly here, but with this float, one never knows!!
Some of yesterday's gains were sure to be short covering ... Check the volume today ... nobody is selling. Let them play their games.
AMES, Iowa, Oct. 01, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NLNK) announced today that the Biomedical Advanced Research and Development Authority (BARDA) of the United States Department of Health and Human Services (HHS) has exercised an $18 million option on NewLink Genetics’ existing contract to support the scale-up of the manufacturing process relating to its investigational rVSV-ZEBOV GP (Ebola) vaccine candidate. BARDA made an initial $30 million contract award to NewLink in late 2014 and is now providing additional funding to continue development of the Ebola vaccine candidate. Merck (MRK), known as MSD outside the United States and Canada, has the license for research, development, manufacturing and commercialization of the rVSV-ZEBOV GP (Ebola) vaccine.
“This additional funding by BARDA will help NewLink and Merck accelerate large-scale production of this Ebola vaccine candidate and demonstrates government commitment to this important project," said Dr. Charles Link, CEO and Chief Scientific Officer of NewLink Genetics. “In collaboration with Merck, we will continue to work diligently to bring this vaccine candidate to patients in need as quickly as possible.”
The rVSV-ZEBOV GP (Ebola) vaccine candidate was originally developed by the Public Health Agency of Canada (PHAC) and was subsequently licensed to a subsidiary of NewLink Genetics. In late 2014, Merck licensed the vaccine from NewLink Genetics to apply Merck's vaccine expertise to help accelerate the development of this vaccine candidate. Clinical studies of the vaccine candidate are ongoing
And, it's pretty hard to dispute entering into P2 trials. They can poo poo the NIH grants all they want ... they aren't just handed out to bogus companies! The likes of SNAKO and his cronies are about to come under a microscope!!